Australian Clinical Labs Ltd (AU:ACL) has released an update.
KKR Entities, including Comet Asia Holdings and KKR Asia III Fund, have become significant shareholders in Australian Clinical Labs Ltd, acquiring a 5.12% voting power through over 10 million fully paid ordinary shares. This development marks a notable investment move, potentially impacting the company’s future market dynamics.
For further insights into AU:ACL stock, check out TipRanks’ Stock Analysis page.